Azithromycin is the drug of choice in the treatment of several bacterial infections, most often those causing middle ear infection, bronchitis, pneumonia, typhoid and sinusitis. It’s also effective against certain urinary tract infections and venereal diseases. This study was carried out to prepare an acceptable suspension either as dry physical mixture powder or granules to be reconstituted, through studying the effect of various type and concentration of suspending agent (xanthan gum, hydroxypropyl methylcellulose (HPMC), either alone or in combination) on the release profile of the drug. The best prepared suspension formulas (H& III) were selected depending on the dissolution profile of each formulas and then compared with the reference suspensions (Zithromax and Azi-once).The viscosity, sedimentation volume, Resuspendability and expiration date were evaluated for the chosen formulas (H&III) and compared with references ZithromaxÃ’ and Azi-onceÃ’.The result indicated that the chosen formula – H had better dissolution rate compared with references suspensions, Also it was less viscous than them.While other chosen formula – III had lower dissolution rate compared with ZithromaxÃ’ and higher dissolution rate than AZi – once, also it was less viscous than both references.It was found that the dry physically mixed powder (formula – H) was more stable than the granular suspension (Formula III) since the expiration date for formula H and formula III were 3.24 and 2.7 years respectively.  Key words: Azithromycin, suspending agent, suspension.

Attempts were made to improve solubility and the liquisolid technology dissolving of medication flurbiprofen. Liquisolid pill was developed utilizing transcutol-HP, polyethylene glycol 400, Avecil PH 102 carrier material and Aerosil 200 layer coating material. Suitable excipient amounts were determined to produce liquisolid powder using a mathematical model. On the other hand, flurbiprofen tablet with the identical composition, directly compressed, was manufactured for comparison without the addition of any unvolatile solvent. Both powder combination characterizations and after-compression tablets were evaluated. The pure drug and physical combination, and chosen liquisolid tablets were studied in order to exclude interacting with the differentional scanning calorimetry (DSC) and fourier transform infrared spectroscopy (FTIR). The results showed that transcutol is the ideal solvent with a solubility of 260±3.9 mg/ml in flurbiprofen. All formula developed were determined to be flowable within the specified limitations. The transcutol-like liquidsolid tablet formula of 35 percent w/w flurbiprofen and carrier to coating ratio of 10 was the most acceptable for the disintegration time, the tablet weight and other approved tablet characteristics. DSC thermographs demonstrated the development of a solid flurbiprofen amorphic solid solution for both the physical blend of the chosen liquisolid system and its tablets. The lack of chemicals interaction in medication and other components of the formula was demonstrated by the retention of all flurbiprofen characteristic peaks in all FTIR spectra. As an option to enhance solubility and dissolve flurbiprofen, which has a poor water solubility, liquisolid tablet has been evaluated.